Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial.
Weimin WangXin YanZhifeng ChengQiqi ZhangRui WangYuying DengJianhua MaDa-Long ZhuPublished in: Diabetes, obesity & metabolism (2023)
Dulaglutide added to basal insulin was efficacious and well tolerated in Chinese patients with T2DM.